Metabolic syndrome, atrial fibrillation, and stroke: Tackling an emerging epidemic

Heart Rhythm

Volumn 12, Issue 11, 2015, Pages 2332-2343

  Hajhosseiny, Reza ^a   Matthews, Gareth K ^b   Lip, Gregory Y H ^c,d  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d AALBORG UNIVERSITY   (Denmark)

Author keywords

Anticoagulation; Atrial fibrillation; Metabolic syndrome; NOACs; Stroke; Warfarin

Indexed keywords

ANTICOAGULANT AGENT;

AGING; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR RISK; CENTRAL AMERICA; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DIETARY INTAKE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EPIDEMIC; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; OBESITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SEDENTARY LIFESTYLE; SOUTH AMERICA; AGE DISTRIBUTION; AGED; BODY MASS; COMORBIDITY; FEMALE; HEALTH; MALE; MIDDLE AGED; NEEDS ASSESSMENT; PATHOPHYSIOLOGY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX RATIO; STROKE; SURVIVAL ANALYSIS; UNITED STATES; VERY ELDERLY;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BODY MASS INDEX; COMORBIDITY; FEMALE; GLOBAL HEALTH; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NEEDS ASSESSMENT; PREVALENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; STROKE; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84945468609     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2015.06.038     Document Type: Article

References (151)

1. C. Medi, G.J. Hankey, and S.B. Freedman Stroke risk and antithrombotic strategies in atrial fibrillation Stroke 41 2010 2705 2713
2. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
3. E.J. Benjamin, P.A. Wolf, R.B. D'Agostino, H. Silbershatz, W.B. Kannel, and D. Levy Impact of atrial fibrillation on the risk of death: the Framingham Heart Study Circulation 98 1998 946 952
4. P. Santangeli, L. Di Biase, R. Bai, and et al. Atrial fibrillation and the risk of incident dementia: a meta-analysis Heart Rhythm 9 2012 1761 1768
5. D. Patel, N.D. Mc Conkey, R. Sohaney, A. Mc Neil, A. Jedrzejczyk, and L. Armaganijan A systematic review of depression and anxiety in patients with atrial fibrillation: the mind-heart link Cardiovasc Psychiatry Neurol 2013 2013 159850
6. D. Lloyd-Jones, R.J. Adams, T.M. Brown, and et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association Circulation 121 2010 e46 e215
7. J. Friberg, P. Buch, H. Scharling, N. Gadsbphioll, and G.B. Jensen Rising rates of hospital admissions for atrial fibrillation Epidemiology 14 2003 666 672
8. W.A. Wattigney, G.A. Mensah, and J.B. Croft Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention Circulation 108 2003 711 716
9. Y. Miyasaka, M.E. Barnes, B.J. Gersh, S.S. Cha, K.R. Bailey, W.P. Abhayaratna, J.B. Seward, and T.S. Tsang Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence Circulation 114 2006 119 125
10. Fuenmayor A.J. Fuenmayor AM. Nonpharmacological treatment of atrial fibrillation. Avances Cardiol 2009;29:286-95.
11. F. Rahman, G.F. Kwan, and E.J. Benjamin Global epidemiology of atrial fibrillation Nat Rev Cardiol 11 2014 639 654
12. E.Q. Wu, H.G. Birnbaum, M. Mareva, E. Tuttle, A.R. Castor, W. Jackman, and J. Ruskin Economic burden and co-morbidities of atrial fibrillation in a privately insured population Curr Med Res Opin 21 2005 1693 1699
13. A. Ringborg, R. Nieuwlaat, P. Lindgren, B. Jonsson, D. Fidan, A.P. Maggioni, J. Lopez-Sendon, J. Stepinska, D.V. Cokkinos, and H.J. Crijns Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation Europace 10 2008 403 411
14. H.S. Jorgensen, H. Nakayama, J. Reith, H.O. Raaschou, and T.S. Olsen Acute stroke with atrial fibrillation: the Copenhagen Stroke Study Stroke 27 1996 1765 1769
15. Global burden of disease. World Health Organization Web site. http://www.who.int/healthinfo/global-burden-disease/GBD-report-2004update-full.pdf. Updated 2004. Accessed March 21, 2014.
16. Aging the Brazilian context. Biblioteca Virtual em Saúde Web site. http://bvsms.saude.gov.br/bvs/folder/10006003219.pdf. Accessed March 20, 2014.
17. World population prospects: the 2012 revision. United Nations, Department of Economic and Social Affairs. Population Division, Population Estimates and Projections Section Web site. http://esa.un.org/unpd/wpp/unpp/panel-population.htm. Accessed December 4, 2014.
18. A.S. Go, E.M. Hylek, K.A. Phillips, Y. Chang, L.E. Henault, J.V. Selby, and D.E. Singer Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 2001 2370 2375
19. L. Friberg, M. Rosenqvist, and G.Y. Lip Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study Eur Heart J 33 2012 1500 1510
20. J.T. Nguyen, and D.G. Benditt Atrial fibrillation susceptibility in metabolic syndrome: simply the sum of its parts? Circulation 117 2008 1249 1251
21. IDF worldwide definition of the metabolic syndrome. International Diabetes Federation Web site. http://www.idf.org/metabolic-syndrome. Accessed April 17, 2015.
22. E.S. Ford Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S Diabetes Care 28 2005 2745 2749
23. J.A. Batsis, R.E. Nieto-Martinez, and F. Lopez-Jimenez Metabolic syndrome: from global epidemiology to individualized medicine Clin Pharmacol Ther 82 2007 509 524
24. D. Yach, C. Hawkes, C.L. Gould, and K.J. Hofman The global burden of chronic diseases: overcoming impediments to prevention and control JAMA 291 2004 2616 2622
25. X. Wu, B. Zhu, L. Fu, H. Wang, B. Zhou, S. Zou, and J. Shi Prevalence, incidence, and mortality of stroke in the Chinese island populations: a systematic review PLoS One 8 2013 e78629
26. M. Wasay, I.A. Khatri, and S. Kaul Stroke in South Asian countries Nat Rev Neurol 10 2014 135 143
27. M. Tadic, B. Ivanovic, and C. Cuspidi What do we currently know about metabolic syndrome and atrial fibrillation? Clin Cardiol 36 2013 654 662
28. S.M. Grundy Metabolic syndrome pandemic Arterioscler Thromb Vasc Biol 28 2008 629 636
29. Obesity and overweight. World Health Organization Web site. http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed March 16, 2014.
30. P.T. James, N. Rigby, and R. Leach International Obesity Task Force. The obesity epidemic, metabolic syndrome and future prevention strategies Eur J Cardiovasc Prev Rehabil 11 2004 3 8
31. S.S. Guo, and W.C. Chumlea Tracking of body mass index in children in relation to overweight in adulthood Am J Clin Nutr 70 1999 145S 148S
32. D.M. Boudreau, D.C. Malone, M.A. Raebel, P.A. Fishman, G.A. Nichols, A.C. Feldstein, A.N. Boscoe, R.H. Ben-Joseph, D.J. Magid, and L.J. Okamoto Health care utilization and costs by metabolic syndrome risk factors Metab Syndr Relat Disord 7 2009 305 314
33. V.S. Malik, W.C. Willett, and F.B. Hu Global obesity: trends, risk factors and policy implications Nat Rev Endocrinol 9 2013 13 27
34. S.W. Lai, K.C. Ng, H.F. Lin, and H.L. Chen Association between obesity and hyperlipidemia among children Yale J Biol Med 74 2001 205 210
35. T.A. Miettinen Cholesterol production in obesity Circulation 44 1971 842 850
36. S.E. Kahn, R.L. Hull, and K.M. Utzschneider Mechanisms linking obesity to insulin resistance and type 2 diabetes Nature 444 2006 840 846
37. R.N. Re Obesity-related hypertension Ochsner J 9 2009 133 136
38. H. Watanabe, N. Tanabe, T. Watanabe, D. Darbar, D.M. Roden, S. Sasaki, and Y. Aizawa Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study Circulation 117 2008 1255 1260
39. B. Dinov, J. Kosiuk, S. Kircher, A. Bollmann, W.J. Acou, A. Arya, G. Hindricks, and S. Rolf Impact of metabolic syndrome on left atrial electroanatomical remodeling and outcomes after radiofrequency ablation of nonvalvular atrial fibrillation Circ Arrhythm Electrophysiol 7 2014 483 489
40. 2 score for the thromboembolic risk stratification of patients with atrial fibrillation Heart Rhythm 11 2014 352 357
41. M.R. Movahed, M. Hashemzadeh, and M.M. Jamal Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease Int J Cardiol 105 2005 315 318
42. R.R. Huxley, K.B. Filion, S. Konety, and A. Alonso Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation Am J Cardiol 108 2011 56 62
43. K. Khavandi, A. Khavandi, O. Asghar, A. Greenstein, S. Withers, A.M. Heagerty, and R.A. Malik Diabetic cardiomyopathy - a distinct disease? Best Pract Res Clin Endocrinol Metab 23 2009 347 360
44. M.K. Rutter, H. Parise, E.J. Benjamin, D. Levy, M.G. Larson, J.B. Meigs, R.W. Nesto, P.W. Wilson, and R.S. Vasan Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study Circulation 107 2003 448 454
45. A. Bissinger, T. Grycewicz, W. Grabowicz, and A. Lubinski The effect of diabetic autonomic neuropathy on P-wave duration, dispersion and atrial fibrillation Arch Med Sci 7 2011 806 812
46. J.S. Healey, and S.J. Connolly Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target Am J Cardiol 91 2003 9 14
47. T. Dawood, and M.P. Schlaich Mediators of target organ damage in hypertension: focus on obesity associated factors and inflammation Minerva Cardioangiol 57 2009 687 704
48. N. Wanahita, F.H. Messerli, S. Bangalore, A.S. Gami, V.K. Somers, and J.S. Steinberg Atrial fibrillation and obesity - results of a meta-analysis Am Heart J 155 2008 310 315
49. T.J. Wang, H. Parise, D. Levy, R.B. D'Agostino Sr, P.A. Wolf, R.S. Vasan, and E.J. Benjamin Obesity and the risk of new-onset atrial fibrillation JAMA 292 2004 2471 2477
50. S.M. Vaziri, M.G. Larson, E.J. Benjamin, and D. Levy Echocardiographic predictors of nonrheumatic atrial fibrillation: the Framingham Heart Study Circulation 89 1994 724 730
51. G. Iacobellis, M.C. Ribaudo, G. Leto, A. Zappaterreno, E. Vecci, U. Di Mario, and F. Leonetti Influence of excess fat on cardiac morphology and function: study in uncomplicated obesity Obes Res 10 2002 767 773
52. F.H. Messerli, H.O. Ventura, E. Reisin, G.R. Dreslinski, F.G. Dunn, A.A. MacPhee, and E.D. Frohlich Borderline hypertension and obesity: two prehypertensive states with elevated cardiac output Circulation 66 1982 55 60
53. S. Engeli, and A.M. Sharma The renin-angiotensin system and natriuretic peptides in obesity-associated hypertension J Mol Med (Berl) 79 2001 21 29
54. Y. Naruse, H. Tada, M. Satoh, and et al. Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: clinical impact of continuous positive airway pressure therapy Heart Rhythm 10 2013 331 337
55. A.R. Menezes, C.J. Lavie, J.J. DiNicolantonio, J. O'Keefe, D.P. Morin, S. Khatib, and R.V. Milani Atrial fibrillation in the 21st century: a current understanding of risk factors and primary prevention strategies Mayo Clin Proc 88 2013 394 409
56. T. Horio, J. Miyazato, K. Kamide, S. Takiuchi, and Y. Kawano Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension Am J Hypertens 16 2003 938 944
57. J.A. Diaz-Peromingo, A. Alban-Salgado, F. Garcia-Suarez, J. Sanchez-Leira, J. Saborido-Frojan, and M. Iglesias-Gallego Lipoprotein(a) and lipid profile in patients with atrial fibrillation Med Sci Monit 12 2006 CR122 CR125
58. M. Annoura, M. Ogawa, K. Kumagai, B. Zhang, K. Saku, and K. Arakawa Cholesterol paradox in patients with paroxysmal atrial fibrillation Cardiology 92 1999 21 27
59. H. Watanabe, N. Tanabe, N. Yagihara, T. Watanabe, Y. Aizawa, and M. Kodama Association between lipid profile and risk of atrial fibrillation - Niigata Preventive Medicine Study Circ J 75 2011 2767 2774
60. A. Pedersen, M.W. Baumstark, P. Marckmann, H. Gylling, and B. Sandstrom An olive oil-rich diet results in higher concentrations of LDL cholesterol and a higher number of LDL subfraction particles than rapeseed oil and sunflower oil diets J Lipid Res 41 2000 1901 1911
61. M.A. Martinez-Gonzalez, E. Toledo, F. Aros, and et al. Extravirgin olive oil consumption reduces risk of atrial fibrillation: the PREDIMED (Prevencion con Dieta Mediterranea) trial Circulation 130 2014 18 26
62. F.L. Lopez, S.K. Agarwal, R.F. Maclehose, E.Z. Soliman, A.R. Sharrett, R.R. Huxley, S. Konety, C.M. Ballantyne, and A. Alonso Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities study Circ Arrhythm Electrophysiol 5 2012 155 162
63. J.K. Ninomiya, G. L'Italien, M.H. Criqui, J.L. Whyte, A. Gamst, and R.S. Chen Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey Circulation 109 2004 42 46
64. S. Kurl, J.A. Laukkanen, L. Niskanen, D. Laaksonen, J. Sivenius, K. Nyyssonen, and J.T. Salonen Metabolic syndrome and the risk of stroke in middle-aged men Stroke 37 2006 806 811
65. M.C. Alessi, and I. Juhan-Vague Metabolic syndrome, haemostasis and thrombosis Thromb Haemost 99 2008 995 1000
66. M. Diamant, R. Nieuwland, R.F. Pablo, A. Sturk, J.W. Smit, and J.K. Radder Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus Circulation 106 2002 2442 2447
67. Napoleone E, A DIS, C. Amore, G. Baccante, C. di Febbo, E. Porreca, G. de Gaetano, M.B. Donati, and R. Lorenzet Leptin induces tissue factor expression in human peripheral blood mononuclear cells: a possible link between obesity and cardiovascular risk? J Thromb Haemost 5 2007 1462 1468
68. I. Mertens, A. Verrijken, J.J. Michiels, M. Van der Planken, J.B. Ruige, and L.F. Van Gaal Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome Int J Obesity 30 2006 1308 1314
69. S.S. Anand, Q. Yi, H. Gerstein, E. Lonn, R. Jacobs, V. Vuksan, K. Teo, B. Davis, P. Montague, and S. Yusuf Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease Circulation 108 2003 420 425
70. A.M. Carter, C.M. Cymbalista, T.D. Spector, and P.J. Grant Heritability of clot formation, morphology, and lysis: the EuroCLOT study Arterioscler Thromb Vasc Biol 27 2007 2783 2789
71. A. Bouzas-Mosquera, F.J. Broullon, N. Alvarez-Garcia, E. Mendez, J. Peteiro, T. Gandara-Sambade, O. Prada, V.X. Mosquera, and A. Castro-Beiras Left atrial size and risk for all-cause mortality and ischemic stroke CMAJ 183 2011 E657 E664
72. M.R. Di Tullio, R.L. Sacco, R.R. Sciacca, and S. Homma Left atrial size and the risk of ischemic stroke in an ethnically mixed population Stroke 30 1999 2019 2024
73. S.M. Grundy, B. Hansen, S.C. Smith Jr, J.I. Cleeman, and R.A. Kahn Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management Circulation 109 2004 551 556
74. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Jama 285 2001 2486 2497
75. K. Esposito, R. Marfella, M. Ciotola, C. Di Palo, F. Giugliano, G. Giugliano, M. D'Armiento, F. D'Andrea, and D. Giugliano Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial Jama 292 2004 1440 1446
76. L. Azadbakht, P. Mirmiran, A. Esmaillzadeh, T. Azizi, and F. Azizi Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome Diabetes Care 28 2005 2823 2831
77. P.D. Thompson, D. Buchner, I.L. Pina, and et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity) Circulation 107 2003 3109 3116
78. J.P. Despres, M.C. Pouliot, S. Moorjani, A. Nadeau, A. Tremblay, P.J. Lupien, G. Theriault, and C. Bouchard Loss of abdominal fat and metabolic response to exercise training in obese women Am J Physiol 261 1991 E159 E167
79. J.L. Foltz, A.L. May, B. Belay, A.J. Nihiser, C.A. Dooyema, and H.M. Blanck Population-level intervention strategies and examples for obesity prevention in children Annu Rev Nutr 32 2012 391 415
80. W.C. Knowler, E. Barrett-Connor, S.E. Fowler, R.F. Hamman, J.M. Lachin, E.A. Walker, and D.M. Nathan Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
81. T. Sugiyama, Y. Tsugawa, C.H. Tseng, Y. Kobayashi, and M.F. Shapiro Different time trends of caloric and fat intake between statin users and nonusers among US adults: gluttony in the time of statins? JAMA Intern Med 174 2014 1038 1045
82. H. Buchwald, Y. Avidor, E. Braunwald, M.D. Jensen, W. Pories, K. Fahrbach, and K. Schoelles Bariatric surgery: a systematic review and meta-analysis JAMA 292 2004 1724 1737
83. L. Sjostrom, K. Narbro, C.D. Sjostrom, and et al. Effects of bariatric surgery on mortality in Swedish obese subjects N Engl J Med 357 2007 741 752
84. H. Buchwald, R. Estok, K. Fahrbach, D. Banel, M.D. Jensen, W.J. Pories, J.P. Bantle, and I. Sledge Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis Am J Med 122 248-256 2009 e245
85. C.W. le Roux, S.J. Aylwin, R.L. Batterham, C.M. Borg, F. Coyle, V. Prasad, S. Shurey, M.A. Ghatei, A.G. Patel, and S.R. Bloom Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters Ann Surg 243 2006 108 114
86. R. Aghamohammadzadeh, A.S. Greenstein, R. Yadav, M. Jeziorska, S. Hama, F. Soltani, P.W. Pemberton, B. Ammori, R.A. Malik, H. Soran, and A.M. Heagerty Effects of bariatric surgery on human small artery function: evidence for reduction in perivascular adipocyte inflammation, and the restoration of normal anticontractile activity despite persistent obesity J Am Coll Cardiol 62 2013 128 135
87. H. Abuissa, P.G. Jones, S.P. Marso, and J.H. O'Keefe Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials J Am Coll Cardiol 46 2005 821 826
88. J. Bosch, S. Yusuf, H.C. Gerstein, J. Pogue, P. Sheridan, G. Dagenais, R. Diaz, A. Avezum, F. Lanas, J. Probstfield, G. Fodor, and R.R. Holman Effect of ramipril on the incidence of diabetes N Engl J Med 355 2006 1551 1562
89. C.M. Ballantyne, A.G. Olsson, T.J. Cook, M.F. Mercuri, T.R. Pedersen, and J. Kjekshus Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S Circulation 104 2001 3046 3051
90. K. Pyorala, C.M. Ballantyne, B. Gumbiner, M.W. Lee, A. Shah, M.J. Davies, Y.B. Mitchel, T.R. Pedersen, and J. Kjekshus Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care 27 2004 1735 1740
91. H.S. Abed, G.A. Wittert, D.P. Leong, and et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial JAMA 310 2013 2050 2060
92. T.A. Pearson, S.N. Blair, S.R. Daniels, and et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases Circulation 106 2002 388 391
93. R.K. Pathak, M.E. Middeldorp, D.H. Lau, and et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study J Am Coll Cardiol 64 2014 2222 2231
94. A.J. Camm, G.Y. Lip, R. De Caterina, I. Savelieva, D. Atar, S.H. Hohnloser, G. Hindricks, and P. Kirchhof focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association Eur Heart J 2012;33 2012 2719 2747
95. N.M. Albert Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications Heart Lung 43 2014 48 59
96. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann Intern Med 146 2007 857 867
97. J.V. Amerena, T.E. Walters, S. Mirzaee, and J.M. Kalman Update on the management of atrial fibrillation Med J Aust 199 2013 592 597
98. A.M. Holbrook, J.A. Pereira, R. Labiris, H. McDonald, J.D. Douketis, M. Crowther, and P.S. Wells Systematic overview of warfarin and its drug and food interactions Arch Intern Med 165 2005 1095 1106
99. P. Gallego, V. Roldan, F. Marin, M. Romera, M. Valdes, V. Vicente, and G.Y. Lip Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation Thromb Haemost 110 2013 1189 1198
100. Y. Wan, C. Heneghan, R. Perera, N. Roberts, J. Hollowell, P. Glasziou, C. Bankhead, and Y. Xu Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review Circ Cardiovasc Qual Outcomes 1 2008 84 91
101. V. Jacobs, S.C. Woller, S. Stevens, and et al. Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia Heart Rhythm 11 2014 2206 2213
102. R. De Caterina, S. Husted, L. Wallentin, and et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease Thromb Haemost 110 2013 1087 1107
103. G.Y. Lip, S. Kamath, M. Jafri, A. Mohammed, and D. Bareford Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation Project Stroke 33 2002 238 242
104. How can we avoid a stroke crisis in Latin America? Working group report: stroke prevention in patients with atrial fibrillation. StopAfib.org Web site. http://www.stopafib.org/downloads/News360.pdf. Accessed March 16, 2014.
105. L.S. Fornari, D. Calderaro, I.B. Nassar, C. Lauretti, L. Nakamura, R. Bagnatori, W. Ageno, and B. Caramelli Misuse of antithrombotic therapy in atrial fibrillation patients: frequent, pervasive and persistent J Thromb Thrombolysis 23 2007 65 71
106. P.G. Macedo, E. Ferreira Neto, B.T. Silva, J.R. Barreto Filho, H. Maia, C. Novakoski, A. Zanatta, E.M. Oliveira, J.M. Rocha, T.N. Seixas, A.K. Peres, and L. Leite Oral anticoagulation in patients with atrial fibrillation: from guidelines to bedside [in Portuguese] Rev Assoc Med Bras 56 2010 56 61
107. I.N. Sabir, G.D.K. Matthews, and C.L.H. Huang Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice Postgrad Med J 89 2013 346 351
108. S. Goto, S. Oh, F. Cools, Y. Koretsune, P. Angchaisuksiri, S.K. Rushton-Smith, G. Kayani, P. Wilkinson, and A.K. Kakkar GARFIELD Investigators. Regional differences in use of antithrombotic therapy for stroke prevention in atrial fibrillation and associated outcomes: European and Asian insights Eur Heart J 34 2013 790 791
109. DC, da Costa IF Sobral Filho, M.E. de Melo, and et al. Main causes of anticoagulation under- utilization in patients with atrial fibrillation and thromboembolic risk factors Replampa 18 2005 222 Abstract 76
110. C. Cantu, A. Arauz, J.L. Ruiz-Sandoval, and et al. Underuse of antithrombotic therapy and clinical outcome in patients with acute ischemic stroke and atrial fibrillation in a Hispanic population Stroke 42 2011 e346 e347
111. S. Husted, R. de Caterina, F. Andreotti, and et al. ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel Thromb Haemost 111 2014 781 782
112. R. De Caterina, S. Husted, L. Wallentin, and et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease Thromb Haemost 109 2013 569 579
113. H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, W. Hacke, J. Oldgren, P. Sinnaeve, A.J. Camm, and P. Kirchhof European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation Europace 15 2013 625 651
114. M.V. Huisman, G.Y. Lip, H.C. Diener, M. Brueckmann, J. van Ryn, and A. Clemens Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice Thromb Haemost 107 2012 838 847
115. A.G.G. Turpie, R. Kreutz, J. Llau, B. Norrving, and S. Haas Management consensus guidance for the use of rivaroxaban - an oral, direct factor Xa inhibitor Thromb Haemost 108 2012 876 886
116. S.J. Connolly, J. Eikelboom, C. Joyner, and et al. Apixaban in patients with atrial fibrillation N Engl J Med 364 2011 806 817
117. M.E. Kleinow, C.L. Garwood, J.L. Clemente, and P. Whittaker Effect of chronic kidney disease on warfarin management in a pharmacist-managed anticoagulation clinic J Manag Care Pharm 17 2011 523 530
118. N. Raghavan, C.E. Frost, Z. Yu, K. He, H. Zhang, W.G. Humphreys, D. Pinto, S. Chen, S. Bonacorsi, P.C. Wong, and D. Zhang Apixaban metabolism and pharmacokinetics after oral administration to humans Drug metabolism and disposition: the biological fate of chemicals 37 2009 74 81
119. J. Stangier, K. Rathgen, H. Stahle, D. Gansser, and W. Roth The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects Br J Clin Pharmacol 64 2007 292 303
120. R.P. Giugliano, C.T. Ruff, E. Braunwald, and et al. Edoxaban versus warfarin in patients with atrial fibrillation N Engl J Med 369 2013 2093 2104
121. Y. Koretsune, T. Yamashita, and M. Yasaka Evaluation of edoxaban in patients with atrial fibrillation and severe renal impairment Eur Heart J 34 2013 XX-XX
122. K. Lee Metabolic syndrome predicts the incidence of hepatic steatosis in Koreans Obes Res Clin Pract 4 2010 e163 e246
123. E.A. Nutescu, N.L. Shapiro, S. Ibrahim, and P. West Warfarin and its interactions with foods, herbs and other dietary supplements Expert Opin Drug Saf 5 2006 433 451
124. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, and et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
125. M.R. Patel, K.W. Mahaffey, J. Garg, and et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
126. C.B. Granger, J.H. Alexander, J.J. McMurray, and et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
127. R.D. Lopes, J.H. Alexander, S.M. Al-Khatib, and et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale Am Heart J 159 2010 331 339
128. U.S. Food and Drug Administration Drug: Xarelto (rivaroxaban) tablets. Indication for use: prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation Briefing document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) 2011 U.S. Food and Drug Administration Silver Spring, MD
129. S.D. Pokorney, M.W. Sherwood, and R.C. Becker Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation J Thromb Thrombolysis 36 2013 163 174
130. J. Mendell, L. Ridout, G. He, and S. Chen An Open-Label, Phase 1 Study to Evaluate the Effects of Hepatic Impairment on Edoxaban Pharmacokinetics 2012 European Society of Cardiology Munich, Germany Abstract 84722
131. G.P. Aithal, C.P. Day, P.J. Kesteven, and A.K. Daly Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications Lancet 353 1999 717 719
132. G. D'Andrea, R.L. D'Ambrosio, P. Di Perna, M. Chetta, R. Santacroce, V. Brancaccio, E. Grandone, and M. Margaglione A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin Blood 105 2005 645 649
133. S. Apostolakis, R.M. Sullivan, B. Olshansky, and G.Y. Lip Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score Chest 144 2013 1555 1563
134. D. Poli, E. Antonucci, S. Testa, and G.Y. Lip A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin Intern Emerg Med 9 2014 443 447
135. P. Gallego, V. Roldan, F. Marin, J. Galvez, M. Valdes, V. Vicente, and G.Y. Lip SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation Am J Med 127 2014 1083 1088
136. G.Y. Lip, K. Haguenoer, C. Saint-Etienne, and L. Fauchier Relationship of the SAMe-TT(2)R(2) score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation Chest 146 2014 719 726
137. V.A. Portnoi The underuse of warfarin treatment in the elderly Arch Intern Med 159 1999 1374 1375
138. A.S. Go, E.M. Hylek, L.H. Borowsky, K.A. Phillips, J.V. Selby, and D.E. Singer Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study Ann Intern Med 131 1999 927 934
139. M.B. Sellers, and L.K. Newby Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients Am Heart J 161 2011 241 246
140. S. Halvorsen, D. Atar, H. Yang, and et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial Eur Heart J 35 2014 1864 1872
141. A. Corsonello, C. Pedone, F. Lattanzio, M. Lucchetti, S. Garasto, C. Carbone, C. Greco, P. Fabbietti, and R.A. Incalzi Regimen complexity and medication nonadherence in elderly patients Ther Clin Risk Manag 5 2009 209 216
142. PRODUCT MONOGRAPH, PrELIQUIS® apixaban tablets, 2.5 mg and 5 mg, Anticoagulant. Pfizer Web site. http://www.pfizer.ca/en/our-products/products/monograph/313. Accessed March 18, 2014.
143. D. Kubitza, M. Becka, M. Zuehlsdorf, and W. Mueck Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 47 Feb 2007 218 226
144. A. Mahlmann, S. Gehrisch, and J. Beyer-Westendorf Pharmacokinetics of rivaroxaban after bariatric surgery: a case report J Thromb Thrombolysis 36 2013 533 535
145. Y.F. Lai, M.H. Cheen, S.H. Lim, F.H. Yeo, S.C. Nah, M.C. Kong, D. Mya, L.H. Lee, and H.J. Ng The effects of fasting in Muslim patients taking warfarin J Thromb Haemost 12 2014 349 354
146. L.C. Lin, R. Watson, and S.C. Wu What is associated with low food intake in older people with dementia? J Clin Nurs 19 2010 53 59
147. S.G. Goodman, D.M. Wojdyla, J.P. Piccini, and et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation) J Am Coll Cardiol 63 2014 891 900
148. Briefing information for the September 20, 2010 meeting of the Cardiovascular and Renal Drugs Advisory Committee. U.S. Food and Drug Administration Web site. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226011.pdf. Accessed March 27, 2014.
149. J. Mendell, H. Zahir, N. Matsushima, R. Noveck, F. Lee, S. Chen, G. Zhang, and M. Shi Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor Am J Cardiovasc Drugs 13 2013 331 342
150. C.T. Ruff, R.P. Giugliano, E.M. Antman, S.E. Crugnale, T. Bocanegra, M. Mercuri, J. Hanyok, I. Patel, M. Shi, D. Salazar, C.H. McCabe, and E. Braunwald Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor Xa next GEneration in Atrial Fibrillation-Thrombolysis in Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) Am Heart J 160 2010 635 641
151. J. Mendell, M. Tachibana, M. Shi, and S. Kunitada Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers J Clin Pharmacol 51 2011 687 694